来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

未开盘 12-05 16:09:08

16.730

-0.020

-0.12%

最高16.900	最低16.380	成交量161.30万
今开16.750	昨收16.750	日振幅3.10%
总市值74.62亿	流通市值74.62亿	总股本4.46亿
成交额2,688万	换手率0.36%	流通股本4.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":16.73,"timestamp":1764922148002,"preClose":16.75,"halted":0,"volume":1613000,"delay":0,"floatShares":446000000,"shares":446000000,"eps":-0.7831335748049884,"marketStatus":"未开盘","change":-0.02,"latestTime":"12-05 16:09:08","open":16.75,"high":16.9,"low":16.38,"amount":26882167,"amplitude":0.031045,"askPrice":16.77,"askSize":1500,"bidPrice":16.73,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-0.7202651296105997,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":0,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":16.75,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":0.6107673782704119,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105/wiki","defaultTab":"wiki","newsList":[{"id":"2589855884","title":"每日卖空追踪 | 来凯医药-B 12月04日卖空量成交23.25万股，卖空比例为5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589855884","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589855884?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:30","pubTimestamp":1764837028,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间12月04日，涨4.69%，卖空量成交23.25万股，较上一交易日增加78.16%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163425978f87fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163425978f87fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2588079060","title":"港股异动 | 来凯医药-B(02105)早盘涨超5% LAE002预计26年上半年提交NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2588079060","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588079060?lang=zh_cn&edition=full","pubTime":"2025-12-04 10:05","pubTimestamp":1764813955,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B早盘涨超5%，截至发稿，涨5.63%，报16.9港元，成交额2869.72万港元。消息面上，来凯医药此前与齐鲁制药签订独家协议，许可齐鲁制药在中国地区进行LAE002 的研究、开发及商业化。甬兴证券发布研报称，LAE002预计26年上半年提交NDA。公司管线推进顺利，LAE002授权予齐鲁，LAE102的MAD数据优秀，LAE103的IND申请已获FDA批准；该行对LAE102采用DCF估值法，首次覆盖，给予公司“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2588048711","title":"决胜港股升浪・致敬卓越力量，“第十届智通财经资本市场年会暨上市公司颁奖盛典”25项大奖揭晓!","url":"https://stock-news.laohu8.com/highlight/detail?id=2588048711","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588048711?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:21","pubTimestamp":1764760876,"startTime":"0","endTime":"0","summary":"2025年12月3日，由国内领先的港美股资讯平台智通财经与中资海外私募基金一站式服务平台新智基金网联合主办、财经公关综合服务提供商冬日暖阳 Donova 独家承办的 “第十届智通财经资本市场年会暨上市公司颁奖盛典” 在深圳盛大启幕。荣耀加冕：231 家企业及管理者斩获 25 项年度大奖当晚的颁奖典礼星光熠熠，各项大奖实至名归。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02627","09699","02556","00017","02498","00363","00875","02256","00460","00135","00777","00861","00960","00136","00656","02419","00267","00992","02511","02525","00305","00384","00699","00020","02121","00382","00867","06160","02142","00999","00826","00300","01070","01833","02105","02279","00512","00003","02380","09678","00302","00855","00666","00451","00798","00884","01093","09878"],"gpt_icon":1},{"id":"1168306811","title":"來凱醫藥（02105）11月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1168306811","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168306811?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:13","pubTimestamp":1764753182,"startTime":"0","endTime":"0","summary":"來凱醫藥有限公司于2025年12月3日发布截至2025年11月30日的股份变动月报。报告显示，公司本月已发行普通股总数为446,466,350股，与上月保持一致，未有新增发行、回购或注销行为。公司表示，在报告期内，暂无认购供股、配股或购回行动，整体股本结构保持不变。在股权激励方面，公司此前已采纳首发前购股权计划及首发后购股权计划。截至月末，首发前购股权计划下24,760,130份期权处于已失效状态，首发后购股权计划下尚有16,630,035股潜在可发行股份。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"gpt_icon":0},{"id":"2588028652","title":"每日卖空追踪 | 来凯医药-B 12月03日卖空量成交8.1万股，卖空比例为6.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588028652","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588028652?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:30","pubTimestamp":1764750624,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间12月03日，跌2.38%，卖空量成交8.1万股，较上一交易日减少47.91%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120316340095286ee9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120316340095286ee9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2588402863","title":"来凯医药-B12月03日遭主力抛售34.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588402863","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588402863?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:15","pubTimestamp":1764749712,"startTime":"0","endTime":"0","summary":"12月03日, 来凯医药-B股价跌2.38%，报收16.00元，成交金额2096.4万元，换手率0.29%，振幅4.76%，量比0.32。来凯医药-B今日主力资金净流出34.8万元，上一交易日主力净流出213.7万元。该股近5个交易日上涨8.65%，主力资金累计净流入2693.9万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入3658.5万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203161545978d718e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203161545978d718e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2588470748","title":"来凯医药-B(02105.HK)涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588470748","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588470748?lang=zh_cn&edition=full","pubTime":"2025-12-01 11:40","pubTimestamp":1764560431,"startTime":"0","endTime":"0","summary":"每经AI快讯，来凯医药-B(02105.HK)涨超4%，截至发稿，涨4.92%，报17.27港元，成交额3214.93万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512013579004939.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512013579004939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2588210710","title":"港股异动 | 来凯医药-B(02105)涨超6% 业内预计LAE002在中国市场销售峰值有望达到20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588210710","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588210710?lang=zh_cn&edition=full","pubTime":"2025-12-01 11:24","pubTimestamp":1764559487,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B涨超6%，截至发稿，涨4.92%，报17.27港元，成交额3214.93万港元。消息面上，11月12日，来凯医药宣布，将其乳腺癌候选新药LAE002 中国地区权益授予齐鲁制药，协议总金额高达20.45亿元。这笔交易是今年国内生物医药领域较大规模的授权合作之一。据悉，LAE002是一种强效AKT抑制剂。业内预计，LAE002在中国市场销售峰值有望达到20亿元，而全球市场表现可参考Capivasertib——该产品今年销售额预计达7-8亿美元，销售峰值有望突破10-20亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MCHI","CQQQ","ASHR","CHAU","KWEB","BK4588","BK4614","DRAG","FXI","BK1161","YINN","BK4585","02105","ASHS","CWEB"],"gpt_icon":0},{"id":"2586906592","title":"港股异动 | 来凯医药-B(02105)再涨超15% 月内累涨超四成 LAE002近期斩获BD大单","url":"https://stock-news.laohu8.com/highlight/detail?id=2586906592","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586906592?lang=zh_cn&edition=full","pubTime":"2025-11-27 10:29","pubTimestamp":1764210561,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B(02105)再涨超15%，月内累计涨幅超40%。截至发稿，涨15.38%，报16.95港元，成交额5821.71万港元。消息面上，11月12日，来凯医药将乳腺癌候选新药LAE002 (afuresertib)中国地区权益授予齐鲁制药，交易总金额达20.45亿元，而且来凯医药还有权收取十余到二十余百分点的梯度销售分成。据券商研报，LAE002国内销售峰值预计20亿元左右，全球销售峰值可参考Capivasertib。Capivasertib今年销售预期7-8亿美元，销售峰值预计10-20亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"港股异动 | 来凯医药-B(02105)再涨超15% 月内累涨超四成 LAE002近期斩获BD大单","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2586700255","title":"每日卖空追踪 | 来凯医药-B 11月26日卖空量成交12.4万股，卖空比例为5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586700255","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586700255?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:30","pubTimestamp":1764145824,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间11月26日，跌1.41%，卖空量成交12.4万股，较上一交易日减少0.8%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163349978052f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163349978052f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2586255747","title":"来凯医药-B盘中异动 早盘急速拉升5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586255747","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586255747?lang=zh_cn&edition=full","pubTime":"2025-11-26 09:56","pubTimestamp":1764122189,"startTime":"0","endTime":"0","summary":"2025年11月26日早盘09时56分，来凯医药-B股票出现波动，股价急速拉升5.03%。截至发稿，该股报15.650港元/股，成交量55.1万股，换手率0.12%，振幅5.57%。资金方面，该股资金流入561.351万港元，流出209.331万港元。机构评级方面，在所有2家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。来凯医药-B股票所在的生物技术行业中，整体涨幅为1.49%。LAE001是雄性激素合成抑制剂,可同时抑制CYP17A1及CYP11B2。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126095630a4ba9abb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126095630a4ba9abb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2585943241","title":"来凯医药-B盘中异动 股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585943241","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585943241?lang=zh_cn&edition=full","pubTime":"2025-11-21 10:12","pubTimestamp":1763691152,"startTime":"0","endTime":"0","summary":"2025年11月21日早盘10时12分，来凯医药-B股票出现异动，股价大幅下跌5.09%。截至发稿，该股报15.110港元/股，成交量111.8万股，换手率0.25%，振幅5.59%。来凯医药-B股票所在的生物技术行业中，整体跌幅为3.82%。其相关个股中，帝王国际投资、方达控股、派格生物医药-B涨幅较大，振幅较大的相关个股有华康生物医学、百奥赛图-B、加科思-B，振幅分别为12.50%、12.06%、11.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511211012329776aa2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511211012329776aa2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2585154271","title":"每日卖空追踪 | 来凯医药-B 11月20日卖空量成交18.75万股，卖空比例为5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585154271","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585154271?lang=zh_cn&edition=full","pubTime":"2025-11-20 16:30","pubTimestamp":1763627426,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间11月20日，涨3.11%，卖空量成交18.75万股，较上一交易日减少80.11%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120163538a4aecb7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120163538a4aecb7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2585194329","title":"来凯医药-B11月20日获主力加仓957.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585194329","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585194329?lang=zh_cn&edition=full","pubTime":"2025-11-20 16:15","pubTimestamp":1763626532,"startTime":"0","endTime":"0","summary":"11月20日, 来凯医药-B股价涨3.11%，报收15.92元，成交金额5531.8万元，换手率0.78%，振幅5.57%，量比0.59。来凯医药-B今日主力资金净流入957.1万元，连续3日净流入，上一交易日主力净流入484.8万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为63.64%，平均涨幅为3.83%。该股近5个交易日上涨33.11%，主力资金累计净流入1673.9万元；近20日主力资金累计净流入1088.7万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112016175797752d76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112016175797752d76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2584999129","title":"来凯医药续涨超7% 8日连涨超50% 乳腺癌明星靶点斩获20.45亿元BD大单","url":"https://stock-news.laohu8.com/highlight/detail?id=2584999129","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584999129?lang=zh_cn&edition=full","pubTime":"2025-11-19 11:11","pubTimestamp":1763521869,"startTime":"0","endTime":"0","summary":"11月19日，来凯医药-B(2105.HK)再度拉升涨超7%，股价重回16港元上方，近8个交易日连涨超50%，总市值71亿港元。消息上，11月12日，来凯医药将乳腺癌候选新药LAE002 (afuresertib)中国地区权益授予齐鲁制药，交易总金额达20.45亿元，而且来凯医药还有权收取十余到二十余百分点的梯度销售分成。有分析称，这是一份含金量十足的大单，来凯有望将以上收益全部揽入怀中。LAE002是全球两种处于晚期临床开发阶段的针对乳腺癌及前列腺癌的AKT抑制剂之一，也就是进度全球前二，国产第一。\n\n港股频道更多独家策划、专家专栏，免费查阅>>\n\r\n            责任编辑：栎树","market":"hk","thumbnail":"http://imgcloud.jrjimg.cn/2025/11/cms_20251119111109449.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2025/11/cms_20251119111109449.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/11/19111154276345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2584096889","title":"来凯医药-B11月18日主力净流入806.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2584096889","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584096889?lang=zh_cn&edition=full","pubTime":"2025-11-18 16:15","pubTimestamp":1763453732,"startTime":"0","endTime":"0","summary":"11月18日, 来凯医药-B股价涨2.68%，报收14.94元，成交金额8323.0万元，换手率1.27%，振幅5.50%，量比1.08。来凯医药-B今日主力资金净流入806.2万元，上一交易日主力净流出279.5万元。该股近5个交易日上涨31.98%，主力资金累计净流出208.1万元；近20日主力资金累计净流出698.2万元，其中净流出天数为14日。该股主力净额占比0.12%，港股市场排名48/2688。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118161746a701550f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118161746a701550f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2584023605","title":"决胜港股升浪·牛启东方2026——第十届智通财经资本市场年会邀您共赴资本盛宴","url":"https://stock-news.laohu8.com/highlight/detail?id=2584023605","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584023605?lang=zh_cn&edition=full","pubTime":"2025-11-18 08:53","pubTimestamp":1763427196,"startTime":"0","endTime":"0","summary":"由港美股第一资讯平台智通财经与中资海外私募基金一站式服务平台新智基金网联合主办，“冬日暖阳” 独家承办，S&P Global Market Intelligence、CITIZEN支持的“第十届智通财经资本市场年会”将于2025年12月3-5日联动深圳与香港两地举行。本届年会以\"决胜港股升浪·牛启东方2026\"为主题，设置六大核心议程，汇聚全球资本力量，共探宽松周期尾声的领涨赛道与中国资产长期增长潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00855","02431","02177","01228","09878","02488","01318","02509","06682","09678","02511","06996","02268","02157","00699","00196","00861","06660","03658","06608","06609","00382","02142","02256","02453","09959","00826","01164","00305","02420","02587","00290","00302","02279","02167","00363","09911","00604","01167","02105","02096","09996","00867","01333","00552","02627","02561","02670","02171","00003"],"gpt_icon":0},{"id":"2584610676","title":"20亿级AKT抑制剂BD背后：来凯与齐鲁的“双向奔赴”","url":"https://stock-news.laohu8.com/highlight/detail?id=2584610676","media":"E药经理人","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584610676?lang=zh_cn&edition=full","pubTime":"2025-11-17 22:12","pubTimestamp":1763388726,"startTime":"0","endTime":"0","summary":"AKT的崛起不算“爆火”，其临床治疗价值在过去两年逐步得到了确认。因此，在实际的临床应用中，AKT抑制剂带来了“耐药后”这一未被满足临床需求的新选择。从研发进度来看，LAE002是全球仅有的两种处于晚期临床开发阶段的针对乳腺癌及前列腺癌的AKT抑制剂。更长远来看，来凯与齐鲁的“联姻”，为产品上市后的商业化打下了好基础。齐鲁此次重金引进LAE002，不仅是齐鲁加码肿瘤创新药的决心，也反映出其对AKT抑制剂这一靶点市场潜力的看好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118013210a6ffdf04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118013210a6ffdf04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","01276","BK1574","02105","BK1161"],"gpt_icon":0},{"id":"2584676629","title":"每日卖空追踪 | 来凯医药-B 11月17日卖空量成交72.25万股，卖空比例为9.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584676629","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584676629?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:30","pubTimestamp":1763368225,"startTime":"0","endTime":"0","summary":"来凯医药-B北京时间11月17日，涨8.42%，卖空量成交72.25万股，较上一交易日减少8.25%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117163359976e7409&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117163359976e7409&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2584612444","title":"来凯医药-B(02105.HK)涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584612444","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584612444?lang=zh_cn&edition=full","pubTime":"2025-11-17 15:08","pubTimestamp":1763363331,"startTime":"0","endTime":"0","summary":"每经AI快讯，来凯医药-B(02105.HK)涨超9%，截至发稿，涨6.71%，报14.32港元，成交额9265.87万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511173566210119.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511173566210119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02105","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":0.4324},{"period":"3month","weight":-0.0188},{"period":"6month","weight":-0.1403},{"period":"1year","weight":0.2504},{"period":"ytd","weight":0.7855}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0058},{"period":"3month","weight":0.0262},{"period":"6month","weight":0.0964},{"period":"1year","weight":0.3336},{"period":"ytd","weight":0.3004}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症、肝脏疾病及肥胖症创新疗法的发现、开发及商业化的投资控股公司。该公司尚处于研发阶段。该公司的在研管线产品包括Afuresertib（LAE002）、LAE001、LAE109、LAE111、LAE112、LAE113、LAE117、LAE118、LAE119、LAE102、LAE103、LAE104、LAE105、LAE106、LAE107、LAE120、LAE123等。Afuresertib是一种三磷酸腺苷（ATP）竞争性AKT抑制剂。LAE001是雄激素合成抑制剂，可同时抑制CYP17A1及CYP11B2。该公司主要在中国、美国、欧洲、韩国等市场开展业务。","exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}